Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT05650190
Active, not recruiting Not applicable

Spectacle Lens Visual Acuity Assessments Study

NCT05650190 · tracked via the Priya Life Science USA tracker
Sponsor
SightGlass Vision, Inc
Phase
Not applicable
Started
2022-12-08
Last updated
2026-05-05

Condition(s) studied

MyopiaMyopia ProgressionJuvenile Myopia

Investigational drug(s) / intervention(s)

Novel spectacle lens designSpectacle lenses

Novel spectacle lens design: Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia

Spectacle lenses: Single vision, impact resistant spectacle lenses

Study summary

This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments.

Eligibility

Sex
ALL
Min age
9 Years
Max age
14 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Existing subject from the CYPRESS Extension study (CPRO-1802-002) * Ability to comply with study assessments * The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed coy of the form Exclusion Criteria: * Any current ocular infection, inflammation or irritation likely to affect vision

Primary outcome measure(s)

  • Visual Acuity — 15 minutes
    Reading Speed (maximum words per minute)

Trial sites (6)

FacilityCityRegionStatus
Sabal Eye Care Longwood Florida
Kannarr Eye Care Pittsburg Kansas
Advanced Eyecare PC Raytown Missouri
SUNY School of Optometry New York New York
Vision Optique Houston Texas
William J Bogus, OD, FAAO Salt Lake City Utah

More SightGlass Vision, Inc. trials in the USA

Myopia Control Spectacle Lens Cessation Study Active, not recruiting
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens Recruiting
Children's Viewing Behavior Recruiting
Control of Myopia Using Novel Spectacle Lens Designs Active, not recruiting
CYPRESS Efficacy and Safety Study Extension Active, not recruiting

Other trials for the same condition

MiSight 1 Day Safety Post-Approval Study Active, not recruiting
Myopia Control Spectacle Lens Cessation Study Active, not recruiting
Evaluation of Two Monthly Silicone Hydrogel Multifocal Toric in Soft Contact Lens Wearers Recruiting
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens Recruiting
Progressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05650190 on ClinicalTrials.gov ↗ ← All trials in the USA